Literature DB >> 19734416

T-cell abnormalities are present at high frequencies in patients with hypereosinophilic syndrome.

Grzegorz Helbig1, Agata Wieczorkiewicz, Joanna Dziaczkowska-Suszek, Miroslaw Majewski, Slawomira Kyrcz-Krzemien.   

Abstract

BACKGROUND: A T-cell clone, thought to be the source of eosinophilopoietic cytokines, identified by clonal rearrangement of the T-cell receptor and by the presence of aberrant T-cell immunophenotype in peripheral blood defines lymphocytic variant of hypereosinophilic syndrome (L-HES). DESIGN AND METHODS: Peripheral blood samples from 42 patients who satisfied the diagnostic criteria for HES were studied for T-cell receptor clonal rearrangement by polymerase chain reaction according to BIOMED-2. The T-cell immunophenotype population was assessed in peripheral blood by flow cytometry. The FIP1L1-PDGFRA fusion gene was detected by nested polymerase chain reaction.
RESULTS: Forty-two HES patients (18 males and 24 females) with a median age at diagnosis of 56 years (range 17-84) were examined in this study. Their median white blood cell count was 12.9 x 10(9)/L (range 5.3-121), with an absolute eosinophil count of 4.5 x 10(9)/L (range 1.5-99) and a median eosinophilic bone marrow infiltration of 30% (range 11-64). Among the 42 patients, clonal T-cell receptor rearrangements were detected in 18 patients (42.8%). Patients with T-cell receptor clonality included: T-cell receptor beta in 15 patients (35%), T-cell receptor gamma in 9 (21%) and T-cell receptor delta in 9 (21%) patients, respectively. Clonality was detected in all three T-cell receptor loci in 4 cases, in two loci in 7 patients and in one T-cell receptor locus in the remaining 7 patients. The FIP1L1-PDGFRA fusion transcript was absent in all but 2 patients with T-cell receptor clonality. Three patients out of 42 revealed an aberrant T-cell immunophenotype. In some patients, an abnormal CD4:CD8 ratio was demonstrated.
CONCLUSIONS: T-cell abnormalities are present at high frequencies in patients with HES.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19734416      PMCID: PMC2738715          DOI: 10.3324/haematol.2008.005447

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  20 in total

Review 1.  The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature.

Authors:  M J Chusid; D C Dale; B C West; S M Wolff
Journal:  Medicine (Baltimore)       Date:  1975-01       Impact factor: 1.889

2.  Brief report: clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome.

Authors:  E Cogan; L Schandené; A Crusiaux; P Cochaux; T Velu; M Goldman
Journal:  N Engl J Med       Date:  1994-02-24       Impact factor: 91.245

3.  A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

Authors:  Jan Cools; Daniel J DeAngelo; Jason Gotlib; Elizabeth H Stover; Robert D Legare; Jorges Cortes; Jeffrey Kutok; Jennifer Clark; Ilene Galinsky; James D Griffin; Nicholas C P Cross; Ayalew Tefferi; James Malone; Rafeul Alam; Stanley L Schrier; Janet Schmid; Michal Rose; Peter Vandenberghe; Gregor Verhoef; Marc Boogaerts; Iwona Wlodarska; Hagop Kantarjian; Peter Marynen; Steven E Coutre; Richard Stone; D Gary Gilliland
Journal:  N Engl J Med       Date:  2003-03-27       Impact factor: 91.245

4.  Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome.

Authors:  F Roufosse; L Schandené; C Sibille; K Willard-Gallo; B Kennes; A Efira; M Goldman; E Cogan
Journal:  Br J Haematol       Date:  2000-06       Impact factor: 6.998

5.  T-cell receptor-independent activation of clonal Th2 cells associated with chronic hypereosinophilia.

Authors:  F Roufosse; L Schandené; C Sibille; B Kennes; A Efira; E Cogan; M Goldman
Journal:  Blood       Date:  1999-08-01       Impact factor: 22.113

6.  Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia.

Authors:  H U Simon; S G Plötz; R Dummer; K Blaser
Journal:  N Engl J Med       Date:  1999-10-07       Impact factor: 91.245

Review 7.  Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936.

Authors:  J J M van Dongen; A W Langerak; M Brüggemann; P A S Evans; M Hummel; F L Lavender; E Delabesse; F Davi; E Schuuring; R García-Sanz; J H J M van Krieken; J Droese; D González; C Bastard; H E White; M Spaargaren; M González; A Parreira; J L Smith; G J Morgan; M Kneba; E A Macintyre
Journal:  Leukemia       Date:  2003-12       Impact factor: 11.528

8.  Synchronous FIP1L1-PDGFRA-positive chronic eosinophilic leukemia and T-cell lymphoblastic lymphoma: a bilineal clonal malignancy.

Authors:  Mathieu Capovilla; Jean-Michel Cayuela; Chrystèle Bilhou-Nabera; Claude Gardin; Remi Letestu; Fanny Baran-Marzak; Pierre Fenaux; Antoine Martin
Journal:  Eur J Haematol       Date:  2007-11-19       Impact factor: 2.997

Review 9.  Diagnostic role of tests for T cell receptor (TCR) genes.

Authors:  E Hodges; M T Krishna; C Pickard; J L Smith
Journal:  J Clin Pathol       Date:  2003-01       Impact factor: 3.411

10.  Clonal populations of T cells in normal elderly humans: the T cell equivalent to "benign monoclonal gammapathy".

Authors:  D N Posnett; R Sinha; S Kabak; C Russo
Journal:  J Exp Med       Date:  1994-02-01       Impact factor: 14.307

View more
  16 in total

Review 1.  Eosinophilic myeloproliferative disorders.

Authors:  Amy D Klion
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

Review 2.  Hypereosinophilic syndrome variants: diagnostic and therapeutic considerations.

Authors:  Florence Roufosse
Journal:  Haematologica       Date:  2009-09       Impact factor: 9.941

Review 3.  Synergy of Interleukin (IL)-5 and IL-18 in eosinophil mediated pathogenesis of allergic diseases.

Authors:  Hemanth Kumar Kandikattu; Sathisha Upparahalli Venkateshaiah; Anil Mishra
Journal:  Cytokine Growth Factor Rev       Date:  2019-05-10       Impact factor: 7.638

4.  Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome.

Authors:  Florence Roufosse; Aurore de Lavareille; Liliane Schandené; Elie Cogan; Ann Georgelas; Lori Wagner; Liqiang Xi; Mark Raffeld; Michel Goldman; Gerald J Gleich; Amy Klion
Journal:  J Allergy Clin Immunol       Date:  2010-10       Impact factor: 10.793

5.  Asymptomatic circulating T-cell clone cause renal polymorphic inflammatory fibrosis.

Authors:  David Ribes; Audrey Casemayou; Hélène El Hachem; Camille Laurent; Céline Guilbeau-Frugier; François Vergez; Suzanne Tavitian; Joost P Schanstra; Dominique Chauveau; Jean-Loup Bascands; Loïc Ysebaert; Stanislas Faguer
Journal:  Clin Exp Nephrol       Date:  2016-12-26       Impact factor: 2.801

Review 6.  How I treat hypereosinophilic syndromes.

Authors:  Amy D Klion
Journal:  Blood       Date:  2015-05-11       Impact factor: 22.113

7.  Imatinib mesylate may induce long-term clinical response in FIP1L1-PDGFRα-negative hypereosinophilic syndrome.

Authors:  Grzegorz Helbig; Marek Hus; Magdalena Hałasz; Marek Dudziński; Agnieszka Więcławek; Małgorzata Stachowicz; Anna Soja; Sławomira Kyrcz-Krzemień
Journal:  Med Oncol       Date:  2011-01-22       Impact factor: 3.064

Review 8.  Clinical overview of cutaneous features in hypereosinophilic syndrome.

Authors:  Sabine Gisela Plötz; Bettina Hüttig; Birgit Aigner; Christian Merkel; Knut Brockow; Cezmi Akdis; Ulf Darsow; Johannes Ring
Journal:  Curr Allergy Asthma Rep       Date:  2012-04       Impact factor: 4.806

Review 9.  Refining the definition of hypereosinophilic syndrome.

Authors:  Hans-Uwe Simon; Marc E Rothenberg; Bruce S Bochner; Peter F Weller; Andrew J Wardlaw; Michael E Wechsler; Lanny J Rosenwasser; Florence Roufosse; Gerald J Gleich; Amy D Klion
Journal:  J Allergy Clin Immunol       Date:  2010-07       Impact factor: 10.793

10.  Marked and persistent eosinophilia in the absence of clinical manifestations.

Authors:  Yun-Yun K Chen; Paneez Khoury; JeanAnne M Ware; Nicole C Holland-Thomas; Jennifer L Stoddard; Shakuntala Gurprasad; Amy J Waldner; Amy D Klion
Journal:  J Allergy Clin Immunol       Date:  2013-08-26       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.